Efficacy and safety of gluten peptide-based antigen-specific immunotherapy (Nexvax2) in adults with coeliac disease after bolus exposure to gluten (RESET CeD): an interim analysis of a terminated randomised, double-blind, placebo-controlled phase 2 study

Lataukset:

Tye-Din, Jason A

Daveson, A James M

Goel, Gautam

Goldstein, Kaela E

Hand, Holly L

Neff, Kristin M

Popp, Alina

Taavela, Juha

Maki, Markku

Isola, Jorma

Williams, Leslie J

Truitt, Kenneth E

Anderson, Robert P

2023

The Lancet gastroenterology & hepatology

Peer reviewed